文献速递妇科

SIP 7:英国宫颈癌预防进展(2025年第二版)

SIP 7: Progress in Cervical Cancer Prevention in the UK (2025 Second Edition).
PubMed 文献 · BJOG · 2025-07-30

本文综述英国宫颈癌预防进展:筛查参与率下降至不足70%, primary screening采用高危HPV检测,阳性者行反射细胞学分流;2008年起全国接种HPV疫苗,接种率约80%,2023年JCVI建议单剂次;自采样与甲基化等分流测试在研究中。

要点

  • 英国筛查参与率下降,年轻女性已低于70%。
  • 高危HPV检测敏感但不特异,阳性者行反射细胞学以选择阴道镜转诊。
  • HPV疫苗使1995年及以后出生者宫颈癌几乎消除。

核心结论

  • 英国宫颈癌预防取得进展,但筛查参与率下降,需继续鼓励筛查和疫苗接种以降低宫颈癌发生率。

研究设计与样本

  • 本文为综述,汇总英国宫颈癌筛查与HPV疫苗接种的进展、证据及未来方向。

主要发现

  • 英国筛查参与率下降,年轻女性降至70%以下。
  • 初筛采用高危HPV检测,阳性样本行反射细胞学以选择阴道镜转诊。
  • 英国全国疫苗接种项目始于2008年,目前接种率约80%。
  • 自2021年起,12-13岁男女学生可在校接种Gardasil9。
  • HPV疫苗接种使1995年及以后出生者宫颈癌几乎消除。

关键数值与推荐

  • 2023年JCVI新指南推荐单剂次HPV疫苗已足够。
  • 全球139/202个国家有宫颈筛查建议,其中48个推荐高危HPV检测。
  • 英国约十分之一宫颈癌女性诊断年龄超过75岁。

临床怎么用

  • 筛查阳性者行反射细胞学以分流阴道镜转诊。
  • 自采样与医生采样准确性相似,可能适合未参加筛查者。
  • 未来方向包括自采样、后疫苗时代调整及提高筛查年龄上限。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cervical cancer remains a preventable yet significant healthcare problem for women globally. The World Health Organization (WHO) announced a call to eliminate cervical cancer in 2018, with recommendations for screening, vaccination, and treatment of precancerous cervical lesions. Screening uptake is on the decline in the UK, particularly for younger women, where the rate has now dropped below 70%. Primary screening is now performed with high-risk human papillomavirus (hrHPV) testing. This test is sensitive, but not specific, meaning it is good at not missing cancers or precancer, but most people who test hrHPV positive will not have cervical cancer or precancer, and therefore testing positive can lead to unnecessary worry. Any samples that test positive for the virus undergo 'reflex' cytology (the process by which cells suspended in liquid are stained and examined under the microscope by those trained to perform this assessment). This means only virus-positive samples are tested to select patients for colposcopy (visualisation of the cervix with special lenses, in a specialist gynaecology clinic). Other possibilities for this triage test, which may improve the accuracy of screening, are currently under investigation and include methylation (a chemical change in DNA that can be measured) testing, and testing for specific markers. HPV type 16 is the most common high-risk strain found globally, including in the UK. The UK national vaccination programme was started in 2008, and uptake in the UK is currently around 80%. Since 2021, Gardasil9 (offering protection against seven hrHPV types and two HPV types that cause genital warts) has been offered to both boys and girls, at school, aged 12-13. In 2023, new guidance from the Joint Committee on Vaccination and Immunisation (JCVI) recommended a single dose as sufficient. HPV vaccination has almost eliminated cervical cancer in those born in or after 1995. Future directions for the screening programme in the UK include self-sampling, adaptations in the post-vaccine era, and increasing the upper age limit of screening. Self-sampling has been shown to be similarly accurate to clinician-taken samples, and may be a good option for those who do not attend for screening, who have been shown to have increased risk of cervical cancer and worse outcomes. One in ten women with cervical cancer in the UK is diagnosed over the age of 75. Globally, recommendations for cervical screening exist in 139/202 countries. Of these, 48 currently recommend hrHPV testing. Efforts must be made to encourage uptake of both screening and vaccination in order to continue to reduce rates of cervical cancer in the UK.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Ellis LB, Bowden SJ, Lyons D, et al. SIP 7: Progress in Cervical Cancer Prevention in the UK (2025 Second Edition). BJOG. 2025. PMID: 40735948. doi:10.1111/1471-0528.18262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。